首頁 > 市場調查報告書 > 製藥

肥胖症

市場調查報告書

商品編碼

1607888

抗肥胖藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按機制（周邊作用藥物、中樞作用藥物）、藥物類型（處方藥、非處方藥）、地區和競爭細分，2019- 2029F

Anti-Obesity Drugs Market - Global Industry Size, Share, trends, Opportunity, and Forecast, Segmented By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs), By Drug Type (Prescription Drugs, OTC Drugs), By Region & Competition, 2019-2029F

出版日期: 2024年12月06日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球抗肥胖藥物市場價值為 26.5 億美元，預計在預測期內將強勁成長，到 2029 年複合年成長率為 16.20%。超重作鬥爭以及僅透過改變生活方式無法實現顯著減肥的人。當其他干預措施（例如飲食和運動）未能成功幫助人們實現更健康的體重時，這些藥物通常由醫療保健專業人員開出，並且人們對抗肥胖藥物相關健康益處的認知的提高預計會對健康產生正面影響。

市場概況
預測期	2025-2029
2023 年市場規模	26.5億美元
2029 年市場規模	64.4億美元
2024-2029 年複合年成長率	16.20%
成長最快的細分市場	處方藥
最大的市場	北美洲

抗肥胖藥物，也稱為減肥藥物或肥胖藥物療法，是專門為幫助肥胖患者更有效地控制體重而設計的藥物。這些藥物通常與全面的體重管理計劃一起開出，其中包括飲食改變、增加體力活動和行為改變。肥胖是一種複雜的疾病，可能有多種潛在原因，包括遺傳因素、荷爾蒙失衡和生活方式選擇。抗肥胖藥物透過不同的機制發揮作用，幫助減肥。某些藥物透過降低食慾和渴望來發揮作用，使個人更容易攝取更少的卡路里。他們經常瞄準大腦的飢餓中心來發出飽腹感的訊號，即使是少量進餐。有些藥物會干擾身體吸收膳食脂肪的能力，導致熱量攝取減少。這些藥物可以減少消化道對飲食脂肪的吸收。

主要市場促進因素

肥胖率上升推動市場成長

醫療保健負擔推動市場成長

生活方式的改變推動市場成長

主要市場挑戰

長期永續性

肥胖的複雜性

改變生活方式

主要市場趨勢

注意作用機制

細分市場洞察

機制洞察

藥物類型見解

區域洞察

Global Anti-Obesity Drugs Market was valued at USD 2.65 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 16.20% through 2029. Anti-Obesity Drugs are primarily used as part of a comprehensive approach to weight management for individuals who are struggling with obesity or overweight and who have not been able to achieve significant weight loss through lifestyle changes alone. These medications are typically prescribed by healthcare professionals when other interventions, such as diet and exercise, have not been successful in helping a person achieve a healthier weight, and increased awareness of the health benefits associated with Anti-Obesity Drugs are expected to positively influence the global market growth.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 2.65 Billion
Market Size 2029	USD 6.44 Billion
CAGR 2024-2029	16.20%
Fastest Growing Segment	Prescription Drugs
Largest Market	North America

Anti-Obesity drugs, also known as weight loss medications or obesity pharmacotherapy, are medications specifically designed to help individuals who are struggling with obesity to manage their weight more effectively. These medications are typically prescribed alongside a comprehensive weight management program that includes dietary changes, increased physical activity, and behaviour modification. Obesity is a complex condition that can have various underlying causes, including genetic factors, hormonal imbalances, and lifestyle choices. Anti-Obesity drugs work through different mechanisms to aid in weight loss. Certain medications work by reducing appetite and cravings, making it easier for individuals to consume fewer calories. They often target the brain's hunger centres to signal a feeling of fullness even with smaller meals. Some drugs interfere with the body's ability to absorb dietary fats, leading to a reduction in calorie intake. These medications can reduce the absorption of dietary fat in the digestive tract.

Key Market Drivers

Rising Obesity Prevalence Drives the Market Growth

The rising prevalence of obesity plays a significant role in driving the growth of the global Anti-Obesity drugs market. As obesity rates continue to rise globally, there is a growing demand for effective treatment options. Many individuals who struggle with obesity are actively seeking ways to manage their weight and improve their health, creating a larger market for Anti-Obesity drugs.

Obesity is associated with numerous health complications such as type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders. These conditions place a significant burden on healthcare systems in terms of medical costs and resources. As healthcare providers seek ways to address this burden, there's a greater interest in offering effective treatments for obesity, including Anti-Obesity drugs. Increased awareness about the health risks of obesity has led to a greater understanding of the importance of weight management. Public health campaigns, educational initiatives, and media coverage have contributed to a more informed population that seeks medical intervention for obesity-related issues.

While lifestyle modifications such as diet and exercise are crucial for managing weight, many individuals find it challenging to achieve and sustain significant weight loss through these methods alone. Anti-Obesity drugs provide an additional tool to help individuals overcome these difficulties and achieve their weight loss goals. In some cases, individuals may desire more rapid weight loss results than what can be achieved through gradual lifestyle changes. Anti-Obesity drugs can provide quicker initial weight loss, which can motivate individuals to continue their weight management efforts. The rising prevalence of obesity has led to increased research into the underlying causes and mechanisms of obesity. This has paved the way for more personalized treatment approaches, where Anti-Obesity drugs can be tailored to an individual's specific biological factors and needs.

Healthcare Burden Drives the Market Growth

The healthcare burden associated with obesity is a significant driver for the growth of the global Anti-Obesity drugs market. Obesity is linked to a range of chronic health conditions such as type 2 diabetes, cardiovascular diseases, hypertension, and certain cancers. These conditions require ongoing medical care, treatment, and management, leading to higher healthcare costs. As the prevalence of obesity increases, so does the financial burden on healthcare systems. Individuals with obesity are at a higher risk of requiring hospitalizations and medical procedures. These may include surgeries related to weight management, such as bariatric surgery, as well as interventions for obesity-related health complications. The increased demand for these services due to obesity-related issues contributes to the overall healthcare burden.

Treating obesity-related conditions often involves prescribing medications to manage blood sugar, blood pressure, and other health parameters. These medications can be costly, especially when required over the long term. Reducing the incidence of these conditions through effective obesity management could potentially lead to cost savings in medication expenses. The management of obesity-related conditions requires a substantial allocation of healthcare resources, including physician visits, diagnostic tests, medical equipment, and personnel. These resources could be reallocated or better utilized if the prevalence of obesity-related health conditions were reduced through effective weight management strategies, including Anti-Obesity drugs. Obesity-related health issues can lead to decreased work productivity, absenteeism, and disability. This affects not only individuals' quality of life but also the overall productivity of the workforce. By addressing obesity and its associated health conditions, the workforce can become healthier and more productive.

Lifestyle Changes Drives the Market Growth

Lifestyle changes play a significant role in driving the growth of the global Anti-Obesity drugs market. Lifestyle changes, including adopting a healthy diet and engaging in regular physical activity, are fundamental components of weight management. Anti-Obesity drugs are often prescribed alongside these lifestyle changes to provide a comprehensive approach to weight loss. Many individuals find it challenging to make significant lifestyle changes on their own. Anti-Obesity drugs can provide initial weight loss results, which can motivate individuals to continue their efforts and adopt healthier habits over the long term. Lifestyle changes can sometimes take time to show noticeable results. Anti-Obesity drugs can help individuals experience faster initial weight loss, which can be encouraging and set them on a positive trajectory.

Weight loss plateaus are common during a weight management journey. Anti-Obesity drugs can help individuals overcome these plateaus, keeping their motivation high and maintaining progress. Lifestyle changes and Anti-Obesity drugs can work synergistically. Lifestyle changes improve overall health and long-term weight management, while drugs provide additional support for those who need extra help. Different individuals respond differently to lifestyle changes. Some may find it easier to adhere to a healthy lifestyle with the assistance of medication. Anti-Obesity drugs offer a more personalized approach to weight management.

Key Market Challenges

Long-Term Sustainability

Many individuals who achieve weight loss through Anti-Obesity drugs may regain weight once they discontinue the medication. This can lead to frustration, decreased patient satisfaction, and reluctance to continue using the drugs. Long-term reliance on medications for weight management may create a sense of dependency, where individuals believe they can only maintain their weight with the help of drugs. This can hinder the development of healthy, sustainable lifestyle habits.

Effective weight management requires adopting and maintaining healthy behaviours related to diet, exercise, and overall lifestyle. Anti-Obesity drugs can't replace the need for these Behavioural changes, and individuals may struggle to transition from medication-reliant weight loss to sustainable lifestyle habits.

The long-term health risks and benefits of certain Anti-Obesity drugs are not always well understood. Individuals and healthcare providers may be concerned about potential side effects, which can impact decisions to continue or discontinue medication. Some individuals may not fully understand the importance of lifestyle changes for maintaining weight loss and may assume that the medication alone is sufficient. A lack of education about the necessity of sustainable habits can hinder long-term success, ultimately impacting market growth in the forecast period.

Complexity of Obesity

The complexity of obesity poses a significant challenge to the global Anti-Obesity drugs market due to the intricate nature of the condition and the various factors that contribute to it. Obesity is not solely a result of overeating and lack of physical activity. It involves a complex interplay of genetic, hormonal, metabolic, environmental, and behavioral factors. Developing drugs that can effectively target these multifaceted aspects is challenging. Individuals with obesity can have diverse underlying causes and mechanisms driving their weight gain. A single drug may not be equally effective for all individuals, leading to variability in treatment responses.

Hormones such as leptin, ghrelin, insulin, and others play a critical role in appetite regulation and metabolism. The complex hormonal interactions make it difficult to design drugs that accurately modulate these pathways without unintended side effects. Genetic factors contribute to an individual's susceptibility to obesity and their response to treatment. Developing personalized medications that consider genetic variations is complex and requires extensive research. Metabolic rates vary widely among individuals, affecting how they respond to different interventions. Anti-Obesity drugs targeting metabolism need to be tailored to individual metabolic profiles.

Lifestyle Modifications

Lifestyle modifications, such as adopting a healthy diet and increasing physical activity, are essential for long-term weight management. This emphasis on behavioral change can potentially reduce the demand for Anti-Obesity drugs, as individuals might prefer non-pharmacological approaches. Some individuals may prioritize lifestyle changes over medication due to concerns about side effects, long-term dependency, or desire for natural solutions. This can lead to reduced demand for Anti-Obesity drugs. Lifestyle modifications can complement the use of Anti-Obesity drugs. Physicians often recommend a combination of medication and lifestyle changes for the most effective and sustainable weight loss outcomes. Lifestyle changes require education and support to be successful. Healthcare providers play a role in educating patients about the importance of balanced nutrition, portion control, and regular exercise. Changing established behaviours is difficult, and relapses are common. This can affect the perception of both lifestyle changes and Anti-Obesity drugs as sustainable solutions.

Key Market Trends

Focus on Mechanism of Action

The focus on the mechanism of action is a significant trend in the global Anti-Obesity drugs market. This trend involves a deeper understanding of the physiological and biochemical processes that contribute to obesity, which in turn guides the development of more targeted and effective medications. Researchers are investing in studies that explore the intricate mechanisms underlying obesity, including hormonal regulation, neural pathways, metabolism, and appetite control. This understanding informs the design of medications that can specifically target these mechanisms for weight loss. Mechanism-based drug development allows for a more personalized approach to obesity treatment. By identifying the specific mechanisms that contribute to an individual's obesity, healthcare providers can select medications that are more likely to be effective for that particular patient. Rather than relying on a single mechanism, some drugs are being designed to target multiple pathways simultaneously. This approach increases the chances of achieving significant and sustained weight loss by addressing the complexity of obesity.

Mechanism-based drugs aim to have a more focused impact on the body, minimizing unintended side effects. By targeting specific pathways, medications can avoid affecting unrelated physiological systems. Drugs developed based on a detailed understanding of mechanisms are more likely to produce substantial weight loss results. This enhanced efficacy can lead to greater patient satisfaction and better treatment outcomes. Many of the newly developed Anti-Obesity drugs are focused on hormonal regulation. Hormones such as leptin, ghrelin, insulin, and GLP-1 play crucial roles in appetite control, energy balance, and metabolism. Drugs that modulate these hormones offer promising avenues for treatment.

Segmental Insights

Mechanism Insights

Based on the category of Mechanism, the peripherally acting drugs segment emerged as the dominant segment in the global market for Anti-Obesity Drugs in 2023. Peripherally acting drugs have gained prominence in the global Anti-Obesity drugs market due to their targeted mechanisms of action and potential for favorable safety profiles. These medications focus on physiological processes that influence appetite, metabolism, and energy balance, often without directly affecting the central nervous system.

Peripherally acting drugs often target hormones involved in appetite regulation, such as GLP-1 (glucagon-like peptide-1) and PYY (peptide YY). These hormones signal feelings of fullness and satisfaction, helping individuals control their food intake. Many peripherally acting drugs work by enhancing the communication between the gastrointestinal tract and the brain, sending signals that reduce hunger and food cravings. By primarily affecting peripheral physiological processes, these drugs may have fewer central nervous system-related side effects like mood changes or interference with neural pathways. Peripherally acting drugs are less likely to have addictive properties compared to drugs that target the central nervous system. This factor enhances their safety profile. These factors are expected to drive the growth of this segment.

Drug Type Insights

Based on the category of Drug Type, the Prescription Drugs segment emerged as the fastest growing segment in the global market for Anti-Obesity Drugs in 2023. These medications are prescribed by healthcare professionals and regulated by authorities such as the U.S. Food and Drug Administration (FDA) to ensure their safety and efficacy. Consequently, Prescribed drugs for obesity are typically available only with a doctor's prescription. This requirement ensures that patients receive proper medical guidance, monitoring, and dosage recommendations.

Prescription medications undergo rigorous clinical trials to demonstrate their safety and effectiveness before gaining regulatory approval. This approval process adds credibility to prescribed Anti-Obesity drugs. Prescribed drugs have a substantial body of clinical evidence supporting their efficacy in weight loss and obesity management. This evidence-based approach contributes to their dominance in the market. Healthcare providers play a key role in evaluating patients' needs, medical history, and potential contraindications before prescribing Anti-Obesity drugs. This personalized approach enhances patient safety. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant region in the global Anti-Obesity Drugs market in 2023, holding the largest market share in terms of value. North America, particularly the United States, has been experiencing a significant obesity epidemic for several decades. High rates of obesity have led to a substantial demand for effective weight management solutions, including Anti-Obesity drugs. The region boasts well-developed healthcare systems, advanced medical facilities, and a strong pharmaceutical industry. This infrastructure supports the research, development, and distribution of Anti-Obesity drugs. North America has a robust research and development ecosystem, with pharmaceutical companies, academic institutions, and research organizations actively engaged in developing new Anti-Obesity drugs. This focus on innovation contributes to the dominance of the region. Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, have approved several Anti-Obesity drugs for clinical use. These approvals lend credibility to the market and foster confidence in prescribed medications.

Key Market Players

Alizyme PLC
Bayer AG
Bristol-Myers Squibb Co
Currax Pharmaceuticals LLC
Hoffmann-La Roche AG
GlaxoSmithKline PLC
Merck & Co. Inc.
Norgine BV
Novo Nordisk AS
Pfizer Inc

Report Scope:

In this report, the Global Anti-Obesity Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Obesity Drugs Market, By Mechanism:

Peripherally Acting Drugs
Centrally Acting Drugs

Anti-Obesity Drugs Market, By Drug Type:

Prescription Drugs
OTC Drugs

Anti-Obesity Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Obesity Drugs Market.

Available Customizations:

Global Anti-Obesity Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Obesity Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Mechanism (Peripherally Acting Drugs, Centrally Acting Drugs)
- 5.2.2. By Drug Type (Prescription Drugs, OTC Drugs)
- 5.2.3. By Region
- 5.2.4. By Company (2023)
5.3. Market Map

6. North America Anti-Obesity Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Mechanism
- 6.2.2. By Drug Type
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anti-Obesity Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Mechanism
    - 6.3.1.2.2. By Drug Type
- 6.3.2. Canada Anti-Obesity Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Mechanism
    - 6.3.2.2.2. By Drug Type
- 6.3.3. Mexico Anti-Obesity Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Mechanism
    - 6.3.3.2.2. By Drug Type

7. Europe Anti-Obesity Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Mechanism
- 7.2.2. By Drug Type
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anti-Obesity Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Mechanism
    - 7.3.1.2.2. By Drug Type
- 7.3.2. United Kingdom Anti-Obesity Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Mechanism
    - 7.3.2.2.2. By Drug Type
- 7.3.3. Italy Anti-Obesity Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Mechanism
    - 7.3.3.2.2. By Drug Type
- 7.3.4. France Anti-Obesity Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Mechanism
    - 7.3.4.2.2. By Drug Type
- 7.3.5. Spain Anti-Obesity Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Mechanism
    - 7.3.5.2.2. By Drug Type

8. Asia-Pacific Anti-Obesity Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Mechanism
- 8.2.2. By Drug Type
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Anti-Obesity Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Mechanism
    - 8.3.1.2.2. By Drug Type
- 8.3.2. India Anti-Obesity Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Mechanism
    - 8.3.2.2.2. By Drug Type
- 8.3.3. Japan Anti-Obesity Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Mechanism
    - 8.3.3.2.2. By Drug Type
- 8.3.4. South Korea Anti-Obesity Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Mechanism
    - 8.3.4.2.2. By Drug Type
- 8.3.5. Australia Anti-Obesity Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Mechanism
    - 8.3.5.2.2. By Drug Type

9. South America Anti-Obesity Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Mechanism
- 9.2.2. By Drug Type
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Anti-Obesity Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Mechanism
    - 9.3.1.2.2. By Drug Type
- 9.3.2. Argentina Anti-Obesity Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Mechanism
    - 9.3.2.2.2. By Drug Type
- 9.3.3. Colombia Anti-Obesity Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Mechanism
    - 9.3.3.2.2. By Drug Type

10. Middle East and Africa Anti-Obesity Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Mechanism
- 10.2.2. By Drug Type
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Anti-Obesity Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Mechanism
    - 10.3.1.2.2. By Drug Type
- 10.3.2. Saudi Arabia Anti-Obesity Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Mechanism
    - 10.3.2.2.2. By Drug Type
- 10.3.3. UAE Anti-Obesity Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Mechanism
    - 10.3.3.2.2. By Drug Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Anti-Obesity Drugs Market: SWOT Analysis

14. Competitive Landscape

14.1. Alizyme PLC
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Product & Services
- 14.1.4. Financials (In case of listed)
- 14.1.5. Recent Developments
- 14.1.6. SWOT Analysis
14.2. Bayer AG
14.3. Bristol-Myers Squibb Co
14.4. Currax Pharmaceuticals LLC
14.5. Hoffmann-La Roche AG
14.6. GlaxoSmithKline PLC
14.7. Merck & Co. Inc.
14.8. Norgine BV
14.9. Novo Nordisk AS
14.10.Pfizer Inc